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M I C R O B I O L O G Y
Ruminococcin C, a promising antibiotic produced by 
a human gut symbiont
Steve Chiumento1*, Clarisse Roblin2,3*, Sylvie Kieffer-Jaquinod4*, Sybille Tachon2, 
Chloé Leprètre1, Christian Basset1, Dwi Aditiyarini1, Hamza Olleik2, Cendrine Nicoletti2, 
Olivier Bornet5, Olga Iranzo2, Marc Maresca2, Renaud Hardré2, Michel Fons6, Thierry Giardina2, 
Estelle Devillard3, Françoise Guerlesquin5, Yohann Couté4, Mohamed Atta1, Josette Perrier2, 
Mickael Lafond2†, Victor Duarte1†
A major public health challenge today is the resurgence of microbial infections caused by multidrug-resistant strains. 
Consequently, novel antimicrobial molecules are actively sought for development. In this context, the human gut 
microbiome is an under-explored potential trove of valuable natural molecules, such as the ribosomally-synthesized 
and post-translationally modified peptides (RiPPs). The biological activity of the sactipeptide subclass of RiPPs 
remains under-characterized. Here, we characterize an antimicrobial sactipeptide, Ruminococcin C1, purified from 
the caecal contents of rats mono-associated with Ruminococcus gnavus E1, a human symbiont. Its heterologous 
expression and post-translational maturation involving a specific sactisynthase establish a thioether network, which 
creates a double-hairpin folding. This original structure confers activity against pathogenic Clostridia and multidrug- 
resistant strains but no toxicity towards eukaryotic cells. Therefore, the Ruminococcin C1 should be considered as 
a valuable candidate for drug development and its producer strain R. gnavus E1 as a relevant probiotic for gut 
health enhancement.
INTRODUCTION
Over the coming decades, it has been estimated that millions of people 
will succumb to bacterial infections mainly due to the emergence of 
multidrug-resistant (MDR) strains (1, 2). As a result, we urgently 
need to discover novel molecules and means to face this major threat. 
Bacteria constitute a treasure trove of multiple classes of natural 
antimicrobial compounds, one of which is ribosomally synthesized 
and posttranslationally modified peptides (RiPPs). RiPPs are bio-
synthesized from a genetically encoded precursor peptide, generally 
containing an N-terminal leader sequence and a C-terminal core 
peptide (3). Among these peptides, sactipeptides constitute a subclass 
of bacteriocins that emerged several years ago (4, 5). Despite spectacular 
advances made with genomic tools, the sactipeptide subclass is currently 
limited to only six members (Fig. 1A) (6–12). Biosynthesis of most 
of these peptides relies on the expression of a gene cluster encoding at 
least one peptide precursor, a maturation enzyme named sactisynthase, 
which places posttranslational modifications, and two proteins, 
namely, an ABC transporter and a signal peptidase, which are 
involved in peptide export and signal peptide cleavage, respectively 
(Fig. 1B) (13).
In silico analysis of a 15-kb genomic fragment from the strictly 
anaerobic Ruminococcus gnavus E1 strain, a Gram-positive Firmicutes 
isolated from the feces of a healthy human, indicated a multi-operonic 
organization controlled by a two-component regulatory system 
(i.e., a regulon) (14). In addition to the genes involved in regulation, 
immunity, and export, the rumC-regulon includes five open reading 
frames (ORFs) (rumC1 to rumC5), which have been suggested to 
encode sactipeptide precursors (Fig. 1C), two ORFs (rumMc1 and 
rumMc2) thought to encode sactisynthases (fig. S1A), and one 
ORF (rumPc) likely to encode Ruminococcin C (RumC) leader 
peptide-specific metallopeptidase from the M16 family (Fig. 1B) 
(15, 16). Furthermore, previous works showed that R. gnavus E1 
produces an anti-Clostridium substance in the rat gut in a trypsin- 
dependent manner (17). This substance was later partially purified, 
identified as RumC isoforms, and shown to be produced exclusively 
in vivo (15, 18, 19).
From a chemical maturation standpoint, sactisynthases intro-
duce intramolecular thioether cross-links between cysteine sulfur 
and the unreactive -carbon of a partner amino acid by a radical- 
based mechanism to produce sactipeptides (Fig. 1D) (20). All of 
the sactisynthases characterized so far have been classified in the 
Radical S-adenosyl-l-methionine (SAM) enzymes superfamily (21). 
Although their radical SAM domain is known to be directly in-
volved in the formation of the thioether linkage, they all contain a 
C-terminal extension called SPASM (Subtilosin A/Pyrroloquinoline 
quinone/Anaerobic Sulfatase/Mycofactocin maturation enzymes) 
domain housing additional [4Fe-4S] clusters (22), for which the 
role is still under debate (12, 23–31). While the number of sacti-
peptides is still limited, interesting biological properties have been 
found regarding their antimicrobial activity and their mode of 
action (5, 8, 32–35).
Here, we report the in vivo and in vitro production of the RumC1 
sactipeptide and its functional and conformational characterizations. 
We highlight the strong antimicrobial activity against Gram-positive 
pathogens including MDR strains and the lack of toxic effect toward 
eukaryotic cells. Therefore, it has a valuable potential for drug 
development, and its producer strain R. gnavus E1 could be used as 
a powerful probiotic.
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RESULTS
In vivo production and purification of RumC1 from R. gnavus 
E1–monoassociated rats
Crost and co-workers (18) previously showed that when the digestive 
tract of axenic rats is colonized with R. gnavus E1 strain, the feces 
obtained and the cecal contents display an anti–Clostridium perfringens 
(anti-Cp) activity, which is genetically correlated with the rumC-regulon 
(Fig. 1B) (15). Consequently, we began our study by attempting to 
purify in vivo–produced RumC isoforms. After 12 days of colonization 
with R. gnavus E1, the feces were collected and the cecal contents of 
monoassociated rats were found to contain an anti-Cp substance 
(Fig. 2A). The expected RumC peptides are 44 amino acid strings 
after the removal of the supposed N-terminal leader sequence of 
19 residues. An ultrafiltration approach based on expected molecular 
weights was used to enrich peptides of interest in the active fraction 
(Fig. 2A). The active soluble fraction was then submitted to three 
consecutives, and optimized chromatographic steps interleaved with 
desalting steps: cationic exchange, size exclusion, and hydrophobic 
C18 reversed-phase chromatography. Throughout the subsequent 
steps, the putative RumC-containing fractions were selected on the 
basis of an anti-Cp assay (Fig. 2A). Nano–liquid chromatography 
combined with mass spectrometry (LC-MS) analyses revealed a 
considerable enrichment of the five RumC isoforms in two consecutive 
fractions of the last purification step (Fig. 2, B and C), which displayed 
anti-Cp activity when combined (Fig. 2A). The masses of the five 
RumC peptides measured were consistently 8 Da less than their 
theoretical masses, as shown for in vivo and synthetically produced 
unmodified RumC1 peptide (Fig. 2, D and F). The iodoacetamide 
alkylation of the RumC-enriched fraction under reducing conditions 
failed to alter the observed masses of native RumC1 peptide, suggesting 
that the four cysteine residues are modified and most likely engaged 
in intramolecular bonds (Fig. 2E). Unlike the cross-links present in 
lantibiotics where thioether bridges are formed between the sulfur 
atom of a cysteine and the -carbon of a corresponding residue, the 
thioether linkages in sactipeptides involve the -carbon (6, 7). This 
specificity is thought to result in opening of the thioether link 
during tandem MS (MS/MS) analyses, leading to the formation of a 
free cysteine and the dehydramino form of the partner amino acid, 
resulting in a two unit mass decrease (36). Higher-energy collisional 
dissociation–based MS/MS analyses of in vivo–produced RumC1 
indicated that residues A12, N16, R34, and K42 are involved in 
thioether bridges (Fig. 3A and table S1). The same strategy was used 
to study the four remaining RumC peptides, and they were all found 
to contain four thioether bridges involving residues at the same 
positions as those identified in RumC1 (fig. S2).
RumC1 presents a novel thioether network
As thioether bridges open during MS/MS analyses, it is impossible 
to assign the different cysteine residues to their amino acid partners. 
Thus, we sought to establish a heterologous expression system allowing 
site-directed mutagenesis to accurately assign the residues involved 
in each thioether bridge. Furthermore, the in vitro production of 
RumC bacteriocins will facilitate future investigations including 
antimicrobial activity assays, structural, functional, and biophysical 
studies. Similar to the approach described by Himes and co-workers 
(37) for the production of subtilosin A in Escherichia coli, we established 
a protocol to produce heterologously the mature form of RumC1 
(mRumC1), consisting of the leader and core peptide sequences. Here, 
the genes encoding the radical SAM enzyme RumMc1 and the RumC1 
peptide were separately cloned into two different plasmids and 
co-expressed in the presence of suf genes (fig. S3, B and C, top and 
middle) (38). The observed mass of mRumC1 was in good agreement 
with the presence of four thioether linkages (Fig. 3B). Reductive 
alkylation of mRumC1 had no effect on its observed molecular 
A
C
βα
B
D
Fig. 1. Biosynthesis of sactipeptides. (A) Thioether network in previously described sactipeptides. Thioether bridges, disulfide bridges, and head-to-tail cyclization are 
indicated by purple, yellow, and black lines, respectively. (B) Gene regulon encoding ruminococcins C, subtilosin A, thuricin CD, and thurincin H. Purple, radical SAM 
enzymes; light blue, precursor peptides; dark blue, transporter systems; green, signal peptidases; yellow, response regulators; pink, immunity systems; and gray, genes of 
unknown function. (C) Alignment of the five RumC peptide isoforms. (D) Thioether bond formation in sactipeptides catalyzed by radical SAM enzymes.
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weight, thus suggesting that the four Cys residues in mRumC1 are 
involved in posttranslational modifications (Fig. 3C). LC-MS/MS 
analyses of mRumC1 confirmed the same four partner residues A, 
N, R, and K, corresponding to A12, N16, R34, and K42 in RumC1 
purified from cecal contents (Fig. 3, A and B). In this sample, 
two peptide fragments, G(-23)-Y21 and A17-A44, were observed, 
corresponding to the N- and C-terminal parts, respectively, of mRumC1. 
Both of these fragments were detected with a 4-Da mass decrease 
(fig. S4, B and C). In good agreement with this observation, the 
C-terminal peptide, with a similar 4-Da loss of mass, was also 
detected in the RumC1-containing fraction from the in vivo prepara-
tion (fig. S4A). These important results suggest that mature RumC1 
contains four thioether bridges, two each in the N- and C-terminal 
regions.
To identify the residues involved in each thioether bridge, four 
Cys to Ala mutants were designed: mRumC1-C3A, mRumC1-C5A, 
mRumC1-C22A, and mRumC1-C26A. All the mutants were produced 
and purified as described for mRumC1. To detect nonbridged 
cysteine residues, mutant mRumC1 samples were first treated with 
iodoacetamide under reducing conditions and then subjected to 
LC-MS/MS experiments. Analyses of the four single mutants revealed 
fairly complex peptide mixtures with many peptide fragments bearing 
alkylated cysteine residues. These data suggest that, during the 
maturation of mRumC1, the formation of a single thioether linkage 
may influence how the three other bridges form, making the structure 
highly labile. Nevertheless, interesting information can be gleaned 
from the fragmentation patterns of selected peptides present in the 
mixture. We focused our attention on the residues identified as 
partners of the four cysteines and for which the mass is either 
unmodified or presents a loss of 2 Da upon mutation of a single 
cysteine. MS/MS analysis of the Q(-10)-A20 peptide observed in the 
mRumC1-C3A mutant showed no mass loss on the N16 residue but 
a 2-Da decrease on A12. These data indicate that a thioether bridge 
forms between C5 and A12 and that the bridging partner for C3 is 
N16 (Fig. 3D, fig. S5A, and table S1). In good agreement, peptide 
F(-5)-A20 from the mRumC1-C5A mutant contains an unmodified 
A12 residue (Fig. 3D, fig. S5C, and table S1). In the mRumC1-C22A 
mutant, the fragmentation of the A17-A44 peptide revealed a 2-Da 
deficit for R34, whereas K42 was unmodified. These observations 
suggest that R34 and K42 are the partners of C26 and C22, respectively 
(Fig. 3D, fig. S5B, and table S1). Together, the MS/MS analyses of 
both wild-type and mutated mRumC1 peptides allowed us to propose 
a structural model for mature RumC1 in which the peptide is folded 
into two distinct structured domains both containing two thioether 
bridges; the two domains are separated by the strictly conserved AGPAY 
amino acid sequence present in all five RumC isoforms (Fig. 3E).
To establish the connectivity of the thioether rings, nuclear magnetic 
resonance (NMR) experiments were performed by using a 13C-, 15N– 
labeled mRumC1 sample after removal of the N-terminal leader 
sequence by trypsin. The [15N, 1H] heteronuclear single-quantum 
coherence (HSQC) spectrum gave well-dispersed peaks, with 39 of 
42 backbone NH signals observed. The backbone NH signals for 
C26, G27, and N28 could not be observed. The sequential assignment 
was made on the basis of the backbone three-dimensional experiments, 
A B
C
D
E
F
Fig. 2. Purification and characterization of the five RumC isoforms produced in vivo. (A) Protocol for extraction from cecal contents to obtain a purified mixture of 
RumCs. Fractions were selected on the basis of their anti-Cp activity throughout the purification steps. PBS, phosphate-buffered saline. (B and C) LC-MS analyses of the 
two fractions containing the different RumC (* and † indicate succinimide and deamidated forms of C5 and C3, respectively). RumC5 was present in two consecutive 
C18 reversed-phase fractions. (D) Deconvoluted mass spectrum of RumC1 eluted at 21.6 min in nano–LC-MS analyses. (E) Deconvoluted mass spectrum of RumC1 after 
dithiothreitol (DTT)/iodoacetamide treatment. (F) Deconvoluted mass spectrum of synthetic unmodified RumC1.
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Fig. 3. Tandem mass spectra of mature RumC1 peptide from in vivo and in vitro preparations and thioether network (see table S1 for theoretical and observed 
masses of interest). (A) Deconvoluted MS/MS spectrum of in vivo–matured RumC1 (1 to 44, bold sequence) showing prominent y/b and c/z fragments induced by 
breaking of the amide bonds preceding the residues bound to cysteines in thioether bridges. The very structured peptide produced high-intensity and unusual internal 
fragments (blue italics), particularly ANSH (A12-H15) and RNANANVA (R34-A41), corresponding to fragments located between two linked residues. (B) Deconvoluted MS/MS 
spectrum of the heterologously matured mRumC1 [containing leader peptide (italics) and four additional GAMD amino acids for cloning purposes (gray italics)], revealing 
the same characteristic fragmentation pattern. Peaks below 500 Da (identical for the y series of in vivo RumC1) are not shown to improve overall visibility. All masses 
considered are monoisotopic masses. M (last peak in each spectrum) corresponds to the nonfragmented peptide. (C) Deconvoluted MS spectrum of mRumC1 after DTT/
iodoalkylation showing no mass increment. Mass of 6694.09 (ammonia loss) corresponds to a succinimide (*) form produced as a by-product of high-temperature reduction 
of RumC1hm before iodoalkylation. (D) Identification of bridging partners. (E) Double-hairpin–like structure of mRumC1. Cysteine residues bridged via thioether bonds 
are shown in purple, and their amino acid partners are indicated in orange.
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including HNCACB, CBCA(CO)NH, HNCA, HN(CO)CA, HNCO, 
and HN(CA)CO. The chemical shifts of the -carbons of A12, N16, 
R34, and K42 were found at 72.2, 68.6, 74.5, and 75.5 parts per million 
(ppm), respectively (fig. S6A). These values are 15 ppm downfield 
compared to the average value observed for unmodified residues. 
This is consistent with the influence of an electronegative atom, 
such as sulfur, being directly attached. Similar chemical shifts were 
reported for the modified -carbon atoms in subtilosin A, thurincin 
H, and thuricin CD (6–9, 39). Analyses of the total correlation 
spectroscopy (TOCSY) and 13C TOCSY-HSQC experiments confirmed 
that A12, N16, R34, and K42 -carbons are fully substituted, with 
no -protons attached. The atomic connectivity of each thioether 
linkage was determined by analyzing the nuclear Overhauser effect 
spectroscopy (NOESY) and 15N NOESY-HSQC data, which show 
through-space interactions between protons that are close to each 
other. Nuclear Overhauser effect (NOE) interactions were observed 
between the -protons of C3 and the amide proton (HN) of N16, 
the -protons of C5 and the HN proton of A12, and the -protons 
of C22 and the HN proton of K42 (fig. S6B). These NOE data 
assigned unambiguously three of the four thioether linkages between 
C3 and N16, C5 and A12, and C22 and K42. The fourth linkage is 
not evident to be assigned because of C26 unresolved peak, but only 
this Cys residue remains to form a thioether bridge with the -carbon 
atom of R34 in mRumC1.
Sequential proteolytic cleavage of mRumC1 is required 
to produce an active form
As we established that in vivo RumC1 and mRumC1 retain the same 
posttranslational modifications, we performed all subsequent anti-
microbial assays using mRumC1. Similar to the chemically synthesized, 
unmodified form of RumC1, mRumC1 had no anti-Cp activity, 
suggesting that the presence of intramolecular thioether bonds is not 
sufficient to produce antimicrobial activity (fig. S7A). As a protective 
strategy for the organisms producing them, RiPPs are in an inactive 
state until their leader peptide is released as proposed by Yang and 
van der Donk (40). We therefore decided to remove the leader peptide 
from mRumC1. After checking the up-regulation of the corresponding 
mRNA by quantitative reverse transcription polymerase chain reaction 
in the cecal contents (fig. S3A), we cloned the rumPc gene encoding 
the putative leader metallopeptidase identified in the rumC-regulon 
to overproduce and purify the recombinant RumPc protein (fig. S3, 
B and C, bottom). RumPc-treated mRumC1 (i.e., mRumC1c) remained 
inactive against Cp (fig. S7C, top). Moreover, RP-C18 and LC-MS 
analyses revealed that mRumC1c retains the FEGSK amino acid motif 
in its N terminus unlike native RumC1 obtained from rat feces (Figs. 2D 
and 3A and fig. S7, B and C). Because Ramare and co-workers (17) 
previously reported a trypsin-dependent anti-Cp activity in the cecal 
contents, we next performed proteolytic digestion of mRumC1c by 
pancreatic trypsin. This sequential treatment led to the complete 
removal of the leader sequence and generated a mature peptide (i.e., 
mRumC1cc) identical to in vivo–produced RumC1, as confirmed 
by high-performance liquid chromatography (HPLC) and MS analyses, 
which was active against Cp (fig. S7, B and C). In good agreement with 
these results, direct treatment of mRumC1 with pancreatic trypsin led 
to the complete removal of the leader peptide sequence within 1 hour 
(fig. S7D). This one-step cleavage was thus subsequently used to prepare 
active mRumC1cc, currently renamed RumC1 (fig. S7, A, B and C).
Considering these results, the hydrophobicity profile, and the 
absence of any kind of signal peptide predicting a subcellular localization 
of RumPc, we can propose an in vivo RumC1 maturation process 
involving (i) an in situ posttranslational modification of the core 
peptide by RumMc1 followed by a partial cleavage of the leader 
peptide by RumPc and (ii) an ex situ cleavage of the five remaining 
N-terminal amino acids of the leader peptide by pancreatic trypsin, 
leading to an active bacteriocin released in the gut microbiome. To 
conclude, the intracellular RumPc cleavage followed by the extra-
cellular trypsin cleavage to produce an active form of a sactipeptide 
represents a perfect example of mutualism between a symbiont and 
its host collaborating to generate an antipathogenic molecule as a 
protective strategy for both.
RumC1 is safe for use against pathogens and MDR bacteria
The antimicrobial spectrum of RumC1 was investigated on a broad 
range of Gram-positive and Gram-negative bacteria, including pathogens 
and MDR strains. For these studies, we used RumC1 produced by 
heterologous expression and activated by trypsin cleavage to determine 
minimal inhibitory concentrations (MICs; Fig. 4A). To distinguish 
between a bactericidal and a bacteriostatic effect, we also determined 
the minimal bacteriostatic concentration (MBC) for each sensitive strain 
(Fig. 4A). RumC1 was highly effective against a range of pathogenic 
Clostridium species with very low MIC and MBC values. An MBC 
value of 1.56 M was observed against Cp, which is the third cause 
of foodborne infections in the United States after Norovirus and 
Salmonella spp. according to the Centers for Disease Control and 
Prevention (CDC). RumC1 is also effective against Clostridium 
difficile (6.25 M < MBC < 12.5 M), one of the main pathogens 
highlighted in the report published by the CDC in 2013 on “Antibiotic 
Resistance Threats in the United States” and categorized as an urgent 
threat for which new antibiotics are needed. Even lower MBC value 
(0.4 M) was measured for Clostridium botulinum, a pathogen 
responsible for foodborne botulism (via a preformed toxin), infant 
botulism (intestinal infection via a toxin-forming C. botulinum), 
and wound botulism. Moreover, RumC1 was also active against a 
range of Gram-positive organisms such as Staphylococcus aureus and 
MDR strains such as vancomycin-resistant Enterococcus faecalis, nisin- 
resistant Bacillus subtilis or methicillin-resistant S. aureus (MRSA) at 
clinically relevant MIC values in the micromolar range of 0.8 to 50 M. 
As expected, RumC1was also active against closely phylogenetically 
related bacteria such as Clostridium coccoides with an MIC value of 
1.56. Although the antimicrobial assays were performed on a relatively 
exhaustive panel of bacteria, it seems that RumC1 is not active against 
Gram-negative bacteria, for which MICs were determined to be >100 M 
(Fig. 4A). Last, except for MRSA, the MBC values were identical 
to the MICs, suggesting that the effect of RumC1 is bactericidal 
(Fig. 4A).
After assessing the activity spectrum of RumC1, we investigated its 
mode of action on Cp cells. As it is well known that many antimicrobial 
peptides have a pore-forming effect, we assessed the permeabilization 
potency of RumC1 following the fluorescent emission of Cp cells 
treated with propidium iodide (PI), a DNA intercalating agent, and the 
incorporation of the nucleic acid dye SYTOX Green by fluorescence 
microscopy. Both fluorescent compounds cannot cross undamaged 
membranes. We used the detergent cetyltrimethylammonium bromide 
(CTAB) and a well-characterized pore-forming bacteriocin, nisin, 
as positive controls. Even after 2 hours of treatment, cells exposed to 
RumC1 showed no PI nor SYTOX Green incorporation, whereas 
permeabilization with nisin resulted in 59% of the maximum PI 
incorporation measured with CTAB and caused 97% of the cells to 
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stain positive for SYTOX Green (Fig. 4, B and C). Accordingly, RumC1 
is unable to insert into total lipids extracts obtained from Cp contrarily 
to nisin and CTAB (fig. S8). Thus, it appears that, unlike most 
bacteriocins targeting Gram-positive bacteria, RumC1 does not have 
a pore-forming action and has most likely an intracellular target. 
RumC1 can also be expected to be supported by an active membrane 
transporter to reach the intracellular compartment. Although most 
peptides acting on intracellular targets are usually active against 
Gram-negative bacteria and have a much narrower spectrum, some 
RiPPs such as thiopeptides have a broad spectrum and have been 
shown to inhibit translation in Gram-positive cells (41). We next 
tried to identify the cellular pathways inhibited by RumC1 through 
phenotype imaging experiments based on the “bacterial cytological 
profiling” method (42) adapted to anaerobic conditions. Membranes 
and DNA from Cp cells were stained with FM4-64FX and 4′,6-diamidino- 
2-phenylindole (DAPI), respectively, and confocal images were acquired. 
Morphological changes on Cp cells induced by treatment with RumC1 
were compared to the phenotypes induced by conventional antibiotics 
with well-characterized mechanisms of action. Treatment with RumC1 
produced three morphotypes affecting cell length and organization, 
as well as DNA condensation (Fig. 4D). No morphological similarities 
were observed in cultures treated either with antibiotics that in-
hibited transcription or cell wall synthesis or even with those causing 
loss of membrane potential (fig. S9, A and B). However, when cells were 
treated with metronidazole, an antibiotic that inhibits nucleic acid syn-
thesis, we observed the three phenotypes identical to those induced by 
treatment with RumC1. How metronidazole affects nucleic acid synthe-
sis remains unclear. Studies suggest that it could act directly on DNA 
and disrupt its structure. Some other studies showed that it indirectly 
inhibits DNA synthesis and repair systems (e.g., mismatch or SOS), 
possibly by disrupting the cell redox system resulting in ribonucleotide 
reductase inhibition (43). Hence, we hypothesize that RumC1 most 
likely inhibits nucleic acid synthesis in a metronidazole-like manner.
Antimicrobial efficiency not only must be sufficient to develop a 
therapeutic molecule but also must be safe for the host. We therefore 
assayed the cytotoxicity of RumC1 on human cells using two intestinal 
(Caco2 and T84) and one gastric (N87) cell lines. On the basis of 
their metabolic activity (via resazurin assays), RumC1 did not affect 
the viability of these cell lines, even at high concentrations of RumC1 
[IC50 (median inhibitory concentration), > 200 M; fig. S10A]. At 
concentrations of RumC1 up to 200 M, metabolic activities of Caco2, 
N87, and T84 cells were at least 90, 80, and 70%, respectively, of the 
activity measured in untreated cells. Furthermore, RumC1 induced 
no hemolysis of human erythrocytes even at high concentrations 
[EC50 (median effective concentration), > 200 M; fig. S10B]. Last, 
no resistance was induced in serial subcultures of Cp exposed daily 
to RumC1, whereas equivalent treatment with metronidazole led to 
the emergence of resistant bacteria with up to 500-fold higher MICs 
(fig. S10C). The high potency of RumC1 against pathogenic strains 
combined with its lack of effect on eukaryotic cells and the absence 
A
B C
D
1MRSA = methicillin-resistant Staphylococcus aureus, 2VER = vancomycin-resistant, 3NR = nisin-resistant.
Fig. 4. RumC1 antimicrobial activity. (A) Activity spectrum of RumC1 against selected Gram-positive strains. MIC and MBC were >100 M for the following Gram-negative 
strains tested: Salmonella enterica (CIP 80.39), E. coli (ATCC 8739), E. coli MR4 (DSMZ 22314), Pseudomonas aeruginosa (ATCC 9027), P. aeruginosa fluoroquinolone 
resistant (CIP 107398), Acinetobacter baumanii (CIP 103572), A. baumanii multiresistant (CIP 110431), and Klebsiella pneumoniae MR4 (DSMZ 26371). (B and C) Membrane 
permeabilization assay on Cp cells treated with RumC1 or nisin based on measurement of PI incorporation (B) or SYTOX Green staining (C). (B) Cells incubated with 
cetyltrimethylammonium bromide (CTAB) were used as a positive lysis control, and untreated cells were used as a negative control. (C) Cells were treated for 15 min before 
staining. Scale bar, 10 m. (D) Confocal imaging of control Cp cells or Cp cells treated with RumC1 or metronidazole. Membranes were stained with FM4-64FX, and DNA 
was stained with DAPI (4′,6-diamidino-2-phenylindole). RumC1 treatment leads to three morphotypes identical to the ones induced by metronidazole (fig. S9). This figure 
shows one of these three morphotypes, i.e., one regular cell associated with a cell three to four times longer and with uncondensed DNA throughout the cells with a few 
spots of highly condensed DNA. Scale bar, 2 m.
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of resistance development makes it a relevant candidate either as 
therapeutic agent or as food safety agent.
DISCUSSION
Through this study, we were able to (i) develop and optimize a protocol 
to purify a natural molecule exhibiting antibiotic activity produced 
by a human intestinal symbiont from cecal contents harvested from 
R. gnavus E1–monoassociated rat and (ii) produce an active recombinant 
form of this RiPP after maturation and sequential and controlled 
proteolytic cleavage to remove the leader peptide, in line with the steps 
naturally occurring in the human gut (Fig. 5). For almost all natural 
RiPPs, the precursor genes encode an unprocessed peptide bearing an 
N-terminal leader peptide in addition to the C-terminal core peptide. 
Although leader peptides have been suggested to play multiple roles 
during RiPPs biosynthesis, such as acting as a secretion signal or as 
a recognition pattern for the maturation enzymes, the protective effect 
of keeping the peptide inactive before secretion remains the most 
notable (3, 44). Several studies on the broad subclasses of RiPPs, the 
classes II and III lantibiotics (e.g., cytolysin, plantaricin W, haloduracin, 
lichenicidin, carnolysin, and flavipeptin or NAI-112, respectively) have 
reported similarities with a two-step activation process using proteases 
(45–51). However, despite the five or six amino acid overhangs 
remaining after the first proteolytic cleavage in mRumC1c, the GG/ or 
GA/ recognition motif usually found in lantibiotics is not conserved 
in the leader peptides of RumC isoforms, in favor of an /FE pattern 
recognized as a cleavage site by RumPc. Broadly, the different classes 
of lantibiotics, namely, I, II, and III, involve subtilisin-like serine 
proteases, papain-like cysteine proteases, and Zn-dependent bifunctional 
(i.e., endo- and aminopeptidase) proteases, respectively, whereas RumPc 
is a monofunctional Zn-metallopeptidase with an endo-mode of 
action recognizing an undescribed motif (/FE) to date. In addition, the 
second step occurring in the maturation process of RumC1 and leading 
to an active form involves the human pancreatic trypsin. Consequently, 
we have identified a two-step cleavage process involving a mono-
functional Zn-metallopeptidase from the symbiont (i.e., RumPc) and a 
serine protease from the host organism (i.e., trypsin) to get an active 
RiPPs. To our knowledge, nothing equivalent has been reported for 
the RiPPs, especially for the lantibiotic and sactibiotic subclasses 
(Fig. 5). Last, through a deep MS study on both the natural isoforms 
of RumC and recombinant forms, we were able to conclude that 
maturation of the bacteriocin involves a radical SAM sactisynthase, 
Fig. 5. Proposed mechanism of maturation and activation of RumC1 in the human gut. After induction of the two-component system, conventional transcription, 
and translation of the gene regulon Ruminococcins C, the intracellular RumC1 maturation process involves (i) an in situ posttranslational modification of the core peptide 
by RumMc1, leading to the inactive mRumC1; (ii) a partial cleavage of the leader peptide by RumPc, leading to the still inactive mRumC1c; (iii) an export in the intestinal 
lumen by RumTc; and (iv) an ex situ cleavage of the five remaining N-terminal amino acids of the leader peptide by pancreatic trypsin, leading to an active mRumC1cc 
(i.e., RumC1).
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RumMc, itself capable of generating four thioether bridges resulting 
in a new folding pattern, which has never yet been described in the 
literature. The discovery of this new double-hairpin structure leads 
us to propose a new subclass of sactibiotics.
We thoroughly characterized the bactericidal activity of RumC1 
and found that, unlike some bacteriocins (e.g., colicine), which are 
defined as “narrow-spectrum,” RumC1 is active against not only a 
broad spectrum of Gram-positive bacteria, including phylogenetically 
R. gnavus–related bacteria such as Cp, C. difficile, and C. botulinum, 
but also more distant bacteria such as S. aureus, including MDR strains. 
Furthermore, our preliminary data suggest a mechanism involving 
inhibition of nucleic acid synthesis in a metronidazole-like manner, 
but additional investigation is needed to corroborate this hypothesis. 
As a result, MICs for RumC1 are in the micromolar range for, e.g., 
C. difficile or Cp. Safety assays on several human cell lines revealed 
no toxicity, and RumC1 does not trigger resistance development 
unlike many conventional antibiotics. This characteristic is essential 
when developing new drugs against pathogens considering the rise 
of MDR strains worldwide. On the basis of all these findings, it is 
highly relevant to consider RumC for the elaboration of therapeutic 
strategies, after drug optimization or in combination with other 
antimicrobial agents or antibiotics, for human or animal health. Cp 
is also a major pathogen affecting poultry, where it causes necrotic 
enteritis associated with up to 50% mortality (52). Consequently, 
R. gnavus E1 or other RumC-like producing bacteria could be 
considered as natural probiotics and administered for the prevention 
against Gram-positive pathogens. Otherwise, sactibiotics and other 
groups of bacteriocins could be helpful in combinatorial therapies 
with other antimicrobial agents including, e.g., antibiotics to reduce 
emergence of resistance or to fight clinical pathogens, and RumC1 
could be considered in that way (32).
Last, from an ecological standpoint, the R. gnavus E1 and human 
partnership constitute a perfect example of mutualism where both 
host and symbiont work together and need each other to produce 
an active bacteriocin to fight a common enemy: an opportunistic 
pathogen for the host and a competitive species for the same ecological 
environment for the symbiont.
MATERIALS AND METHODS
Animals and sample collection
Animal experiments were performed according to the guidelines of the 
French Ethics Committee, i.e., agreement no. A78-322-6. Axenic male 
F344 M rats (6 weeks old) provided by the Germ Free Animals facility 
ANAXEM (Animalerie Axénique de Micalis) platform [Institut 
National de la Recherche Agronomique (INRA), UMR 1319 Micalis, 
France] and maintained on a standard diet during 12 days were inoc-
ulated with R. gnavus E1 [0.5 ml of late log- phase culture at 109 colony- 
forming units (CFU)/ml] by intragastric route to generate R. gnavus 
E1 monoxenic rats (n = 10). After 5 days, individual fecal samples 
were collected and bacterial counts were estimated by plating serial 
dilutions of suspensions. We plated these samples on Brain Heart 
Infusion agar supplemented with yeast extract (5 g/liter) and hemin 
(5 mg/liter) (BHI-YH), and on Luria-Bertani (LB) agar, under aerobic 
and anaerobic conditions, to check for the colonization by R. gnavus 
E1 and possible contamination by other bacteria. The animals were 
sacrificed 12 days after inoculation, and feces and cecal contents were 
collected. Samples were frozen in liquid nitrogen before being stored 
at −80°C until RNA or bacteriocin purification.
Bacteriocin purification
Cecal contents of R. gnavus E1 monoxenic rats were diluted in 
phosphate-buffered saline (PBS) (10 g for 30 ml) supplemented with 
a protease inhibitor cocktail (cOmplete ULTRA tablets EDTA-free, 
Roche). The suspension was centrifuged at 10,000g for 15 min. 
Resuspension and centrifugation were repeated twice in half the 
initial volume of PBS. The three supernatants were pooled and 
filtered on a polyethersulfone membrane with a 10-kDa cutoff (Merck). 
The resulting filtrate, containing small molecules including peptides, 
was submitted to ion exchange chromatography using a Carboxymethyl 
Sepharose column (GE Healthcare) at 4°C. Elution was performed 
at 2 ml/min with 20 mM acetate sodium buffer at pH 6.5 under 
isocratic conditions for 36 min, followed by a linear 0 to 0.5 M sodium 
chloride gradient for 60 min with a detection at 214 and 280 nm. 
Elution fractions were desalted by DSC-18-SPE columns (Sigma- 
Aldrich). Briefly, samples were loaded after dilution (1:1) in 0.1% 
trifluoroacetic acid (TFA), washed with 0.1% TFA, and eluted in 
90% acetonitrile (ACN) and 0.1% TFA before being lyophilized and 
resuspended in water. Fractions displaying anti-Cp activity (as 
described below) were further purified by size exclusion chromatography 
using a Superdex 30 Increase column (GE Healthcare). Elution was 
performed at 4°C at 0.5 ml/min for 120 min under isocratic conditions 
with PBS, and collected fractions were desalted as described above. 
Active fractions were then applied to a Jupiter 15-m C18 300 Å 
analytical reverse-phase HPLC column (250 mm by 21.2 mm; 
Phenomenex). Peptides were eluted at 1 ml/min with a 0 to 40% linear 
gradient of 90% ACN and 0.1% TFA for 30 min before being lyophilized 
and resuspended in water. The different fractions were maintained at 
4°C during all purification steps and stored at −20°C. The protein con-
centration was estimated either by the Bradford coloration method 
using a bovine serum albumin standard curve or by measuring the 
A280 and using the theoretical extinction coefficient of 8480 M−1 cm−1.
Bacteriocin activity assays
To track the presence of the bacteriocin along the purification, samples 
were tested for their antimicrobial activity against Cp at each step 
using the diffusion assay. If needed, samples were concentrated using 
a Speed-Vac concentrator (Thermo Fisher Scientific). A 10−3 dilution 
of an overnight culture of Cp strain [American Type Culture Collection 
(ATCC) 13124] was spread on BHI-YH agar. After drying for 30 min 
at room temperature, wells with a diameter of 6 mm were dug with a 
Pasteur pipette and 100 l of sample was added per well. Alternatively, 
10 l was spotted directly onto the plate. The presence of inhibition 
halos around the samples was examined after incubation of the 
plates at 37°C for 24 hours under anaerobic conditions.
Expression and purification of MBP-RumC1
A synthetic plasmid containing the E. coli codon-optimized gene of 
R. gnavus E1 encoding RumC1 (pETM-40-rumC1, kanamycin resistant) 
was obtained from GenScript (Piscataway, NJ), which allows the ex-
pression of a MBP (maltose-binding peptide)–tagged peptide. A 
tobacco etch virus nuclear-inclusion-a endopeptidase (TEV protease) 
site was inserted in the linker between MBP and RumC1 peptide. 
pETM40-rumC1 was used to transform competent E. coli BL21 (DE3) 
cells for expression. The resulting E. coli BL21 (DE3) strain was 
grown in M9 medium containing kanamycin (50 g/ml), vitamin B1 
(0.5 g/ml), MgSO4 (1 mM), and glucose (4 mg/ml) at 37°C. At an 
optical density (OD600) of 0.8, the culture was induced using 1 mM 
isopropyl--d-thiogalactopyranoside (IPTG). The temperature was 
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reduced to 25°C, and the cells were grown for 15 hours under stirring. 
Cells were then harvested by centrifugation at 4000 rpm for 20 min 
at 4°C. Cell pellet was suspended in 40 ml of buffer A [50 mM tris 
(pH 8) and 50 mM NaCl] supplemented with one tablet of a protease 
inhibitor cocktail (cOmplete, EDTA-free Protease inhibitor cocktail 
tablets, Roche). Cell pellet was then sonicated, and the lysate was 
clarified by centrifugation at 40,000 rpm for 40 min at 4°C. The super-
natant was collected and passed over Dextrin Sepharose High Per-
formance columns (5 ml; MBPTrap HP, GE Healthcare) coupled to 
a fast protein liquid chromatography (FPLC) (ÄKTA Purifier 900, 
ÄKTA FPLC Systems, GE Healthcare). Columns were washed with 
four column volumes of buffer A. MBP-RumC1 was eluted with 
buffer B [50 mM tris (pH 8), 50 mM NaCl, and 40 mM maltose]. 
Fractions containing MBP-RumC1 were pooled and concentrated in 
a 30,000 molecular weight cutoff (MWCO) filter using Amicon Ultra 
centrifugal filter devices. The sample was digested by TEV protease for 
a final TEV protease:MBP-RumC1 ratio of 1:20 (w/w) and incubated 
for 30 min at room temperature. MBP-tag, TEV protease, and un-
modified RumC1 were separated by loading over a HiLoad 16/60 
Superdex 75 prep grade column (GE Healthcare) equilibrated in 
buffer C [50 mM Hepes and 100 mM NaCl (pH 7.5)]. The peptide 
concentration was estimated by ultraviolet- visible (UV-vis) spectros-
copy on a Cary 50 UV-vis spectrophotometer (Varian) by using an 
extinction coefficient of 8480 M−1 cm−1 at 280 nm.
Heterologous expression and purification of  
mature mRumC1
A synthetic plasmid containing the E. coli codon-optimized gene of 
R. gnavus E1 encoding RumMc1 (pET-15b-rumMc1, ampicillin 
resistant) was obtained from GenScript. Plasmids pET-15b-rumMc1, 
pETM-40-rumC1, and psuf (chloramphenicol resistant) containing 
sufABCDSE genes were used to transform competent E. coli BL21 
(DE3) cells for expression. The resulting strain was grown in M9 
medium containing kanamycin (50 g/ml), amp (100 g/ml), chl 
(34 g/ml), vitamin B1 (0.5 g/ml), FeCl3 (50 M), MgSO4 (1 mM), 
and glucose (4 mg/ml) at 37°C. At an optical density (OD600) of 0.8, 
FeCl3 (100 M) and l-cysteine (300 M) were added and the culture was 
induced using 1 mM IPTG. The temperature was reduced to 25°C, and 
the cells were grown for 15 hours under stirring. Cells were then har-
vested by centrifugation (4000 rpm for 20 min at 4°C). Mature MBP-
mRumC1 was then purified as described above for unmodified RumC1.
RumPc production and purification
A synthetic plasmid containing the E. coli codon-optimized synthetic 
gene of R. gnavus encoding RumPc (pET-21a–rumPc, ampicillin- 
resistant) was obtained from GenScript. In silico analysis on the 
rumPc-encoding gene to identify a putative signal peptide was 
performed by using the SignalP 5.0 server (www.cbs.dtu.dk/services/
SignalP/). The plasmid was transformed into thermo-competent BL21 
(DE3) E. coli cells. Ampicillin-resistant colonies were isolated and 
subcultured in LB broth. Subcultures were used to inoculate 1 liter 
of terrific broth (TB) medium supplemented with ampicillin (final 
concentration, 100 g/ml). The culture was initiated at OD600 = 0.05 in 
prewarmed medium and incubated at 37°C for 1.5 hours and 28°C 
for 40 min (until OD600 = 0.5). Expression was then induced using 
0.5 mM IPTG, and the culture was incubated for 3.5 hours at 28°C. Cells 
were harvested by centrifugation (5000g, 20 min, 4°C) and frozen at 
−20°C. Cells were lysed in buffer D [50 mM NaH2PO4 (pH 7.5) and 
150 mM NaCl] using a cell disrupter (Série TS, CellD, Constant Systems). 
The soluble fraction of the cell lysate was retrieved by centrifugation 
(14,000g, 30 min, 4°C) and filtered at 0.22 m before being submitted 
to a 1-ml HisTrap HP purification affinity column (GE Healthcare) 
according to the manufacturer’s instructions. RumPc was eluted using 
a 0 to 500 mM gradient of imidazole. Pooled fractions containing 
RumPc (detected by SDS–polyacrylamide gel electrophoresis) were 
ultrafiltered through a PES (polyethersulfone) 10-kDa MWCO mem-
brane and washed 10 times in buffer C. The protein concentration was 
estimated by measuring the A280 and using an extinction coefficient 
of 52,425 M−1 cm−1.
mRumC1 leader peptide cleavage
Maturated RumC1 obtained by heterologous coexpression of rumC1 
and rumMc1 genes in E. coli and purified as described above was treated 
with either RumPc or TPCK (N-tosyl-l-phenylalanine chloro-
methyl ketone)–treated trypsin (Sigma-Aldrich) for 1 hour at 37°C. 
The molar ratios used were 200:1 for mRumC1:trypsin and 1:5 for 
mRumC1: RumPc. mRumC1c and mRumC1cc were purified using 
RP-C18-HPLC with the following gradient: 10 min at 22% followed 
by 12 min from 22 to 38% of 90% ACN and 0.1% TFA. For the 
preparation of large amounts of mRumC1cc for biological activity 
assays, mRumC1 was cleaved with trypsin and purified with the 
above RP-C18-HPLC conditions on a preparative column (250 mm 
by 21.2 mm; Phenomenex, Jupiter, 15 m, 300 Å).
Nano–LC-MS/MS analyses
RumC fractions were generally injected at a concentration of 0.1 M. 
Samples were diluted in 5% (v/v) ACN and 0.1% (v/v) TFA and 
analyzed by online nano–LC-MS/MS (NCS HPLC, Dionex, and 
Q Exactive HF, Thermo Fisher Scientific). Peptides were sampled 
on a 300 m by 5 mm PepMap C18 precolumn and separated on a 
75 m by 250 mm PepMap C18 column (Dionex). The nano-LC 
method consisted of a 40 min gradient at a flow rate of 300 nl/min, and 
MS and MS/MS data were acquired using Xcalibur (Thermo Fisher 
Scientific). Highly sensitive method (by increasing the ion time in 
the trap to 200 ms) in MS/MS was used to improve the signal to noise 
of the fragmented large peptides. For the analysis of the maturated 
forms, combined high collision dissociation energies of 20 to 27 were 
used to promote the breaking of both weak bonds (thioether bridge) 
and stronger bonds (amide bonds). Both MS/MS spectra were summed 
up to give a combined spectrum. Parallel reaction monitoring experi-
ments were also conducted to target the species of interest.
MS data analyses
Data were processed automatically using Mascot Distiller software 
(version 2.5.1, Matrix Science) followed by Mascot (version 2.6) 
searches using the sequences of the different peptides of interest as da-
tabase. None was chosen as enzyme, and the precisions were set at 
10 ppm for the peptide precursor and 20 milli mass unit for the frag-
ments. At first instance, many different possibilities of variable mod-
ifications were tested to find out on which amino acid was observed 
in the dehydramino modification (−2H) (36). Manual annotations 
were performed in parallel to Mascot searches to assess the posi-
tions of thioether linkages. For final searches, dehydramino (A, N, R, 
and K), deamidation (NQ), and ammonia loss (N) were set as vari-
able modifications. Qual Browser and Xtract (Thermo Fisher Scien-
tific) were used for the display and the deconvolution of the spectra. All 
considered experimental masses were monoisotopic and nonproton-
ated masses.
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Antimicrobial activity
All targeted strains were grown at 37°C in LB broth under aerobic 
conditions (200 rpm), except for Clostridia that were grown in BHI-
YH under anaerobic conditions (in a Trexler-type anaerobic chamber, 
without stirring). Peptides dissolved in sterile distilled water were 
sterilized 2 min under UV light and added to sterile F-bottom poly-
propylene 96-well microplates from 100 to 0.1 M. Twofold series 
dilutions were performed in cell suspension of each bacterial target, 
including Cp, at 10−4 OD600 units. For other Clostridia, higher con-
centrations of bacteria (i.e., cell suspensions at 10−3 OD600 units) were 
used. MIC was defined as the lowest concentration of peptide that 
inhibited the visible growth of bacteria after 24 to 48 hours incubation 
at 37°C. Cell suspensions were then plated on appropriate solid 
medium devoid of any antimicrobial agent to evaluate bacterial growth. 
MBCs were defined as the lowest concentration of peptide that inhibited 
the visible growth of bacteria after 24 to 48 hours incubation at 37°C 
on a solid medium. MICs and MBCs were determined three times. 
Sterility and growth controls were prepared for each assay.
Membrane permeability assay
Permeabilization of the bacterial membrane by RumC1 was measured 
using the cell-impermeable DNA/RNA probe PI as previously 
explained (53, 54). A bacterial culture of Cp was grown until it 
reached 109 bacteria/ml and then centrifuged for 5 min at 300s. Bacteria 
pellet was then resuspended in sterile PBS in the original volume. PI 
(Sigma-Aldrich) was then added to the suspension at a final concen-
tration of 60 M. One hundred microliters of this suspension was then 
transferred into 96-well black plate (Greiner Bio-One) and treated 
with RumC1 or nisin at 5× their MIC values. Water and CTAB 
diluted at 300 M final concentration were used as negative and positive 
controls, respectively. After 15- and 120-min incubations at 37°C 
under anaerobic conditions, fluorescence was measured (excitation 
at 530 nm and emission at 590 nm) using a microplate reader (Synergy 
Mx, BioTek). Results were expressed as the percentage of total 
permeabilization obtained by treatment with CTAB. All experiments 
were done in triplicate. For the permeabilization assay with SYTOX 
Green (Thermo Fisher Scientific), an overnight culture of Cp was 
diluted at 1:100 in BHI-YH and grown at 37°C under anaerobic 
conditions until OD600 = 0.2. Cells were then treated with RumC1 
or nisin at 5× their MIC values for 15 min before being stained with 
SYTOX Green at 0.5 M. Then, cells were rinsed with Hanks’ 
balanced salt solution +/+ (Gibco) and resuspended in VECTASHIELD 
(Vector Laboratories, CliniSciences H-1000). Observations were lastly 
performed with a Leitz DMRB microscope (Leïca), equipped with a 
Leïca DFC 450C camera.
Study of the mode of action based on phenotype imaging by 
confocal microscopy
Phenotype observations by confocal microscopy were used to evaluate 
the mode of action of RumC1, as previously described (42) but with some 
modifications. An overnight culture of Cp was diluted at 1:100 in BHI-YH 
and grown at 37°C under anaerobic conditions until OD600nm = 0.2. 
Bacteria were then treated with RumC1 or antibiotics with known 
mechanisms of action (fig. S7) at 5× their MIC values for 2 hours. 
Then, membranes were stained with FM4-64FX (Thermo Fisher 
Scientific), and DNA was stained with DAPI (Sigma-Aldrich) at final con-
centrations of 12 and 2 g/ml, respectively, for 10 min on ice. Cells were 
then pelleted (7500 rpm, 30 s) and washed with cold PBS. Cells were fixed 
with 4% cold paraformaldehyde for 15 min on ice before being washed 
with cold PBS again. Last, cells were resuspended in VECTASHIELD, 
and 8 l was transferred onto microscope glass slides. Images were 
collected using an IX71 FluoView confocal microscope (Olympus, Rungis, 
France) for DAPI laser/filter ExWave = “405”/EmWave = “461” and 
for FM4-64FX laser/filter ExWave = “543”/EmWave = “618.”
Cytotoxic assays
The intestinal toxicity of RumC1 was evaluated on human cell lines, 
with NCI-N87 (ATCC CRL-5822), Caco-2 (ATCC HTB-37), and T84 
(ATCC CCL-248) being used as models of human gastric, small 
intestinal, and colonic epithelial cells, respectively. Cells were cultured 
in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal 
bovine serum, 1% l-glutamine, and 1% streptomycin-penicillin antibiotics 
(all from Invitrogen). Cells were routinely seeded and grown onto 25-cm2 
flasks maintained in a 5% CO2 incubator at 37°C. Before cytotoxicity 
assay, cells grown on 25-cm2 flasks were detached using trypsin-EDTA 
solution (Thermo Fisher Scientific), counted using Malassez counting 
chamber, and seeded into 96-well cell culture plates (Greiner Bio-One) 
at approximately 104 cells per well. The cells were left to reach 
confluence for 48 to 72 hours at 37°C in a 5% CO2 incubator. Plates 
were then aspirated, and increasing concentrations of RumC1 (final 
concentrations ranging from 0 to 200 M) diluted in culture medium 
were added to the cells for 48 hours at 37°C in a 5% CO2 incubator. 
Sterile water was used as a negative control. At the end of the incubation, 
wells were empty and cell viability was evaluated using a resazurin- 
based in vitro toxicity assay kit (Sigma-Aldrich) following the man-
ufacturer’s instructions (55). Briefly, wells were aspirated and filled 
with 100 l of diluted resazurin solution obtained by dilution of the 
resazurin stock solution (1:100) in sterile PBS containing calcium and 
magnesium [PBS++ (pH 7.4), Thermo Fisher Scientific]. After 4 hours 
of incubation at 37°C, fluorescence intensity was measured using a 
microplate reader (Synergy Mx, BioTek) with an excitation wavelength 
of 530 nm and an emission wavelength of 590 nm. The fluorescence 
values were normalized by the control and expressed as the percentage 
of cell viability. All experiments were done in triplicate.
Hemolytic activity assay
The hemolytic activity of RumC1 was evaluated as previously described 
(53, 56, 57). Briefly, human erythrocytes (obtained from DivBioScience, 
NL) were pelleted by centrifugation at 800g for 5 min. Cell pellet was 
then resuspended in sterile PBS and centrifuged at 800g for 5 min. This 
step was repeated three times, and erythrocytes were lastly resuspended 
in PBS at a concentration of 8%. One hundred microliters were then 
added per well of sterile 96-well microplates (Greiner Bio-One) 
containing 100 l of PBS with increasing concentrations of RumC1 
(final concentrations ranging from 0 to 200 M) obtained by twofold 
serial dilutions. Sterile water and Triton X-100 diluted in PBS at 
0.1% (v/v) were used as negative and positive controls, respectively. 
After 1 hour at 37°C, the microplates were centrifuged at 800g for 
5 min. One hundred microliters of cell supernatants was collected 
and transferred to a new 96-well microplate, and OD405nm was measured 
using a microplate reader (Synergy Mx, BioTek). Hemolysis caused 
by RumC1 was expressed as the percentage of total hemolysis given 
by treatment with Triton X-100 at 0.1%. All experiments were done 
in triplicate.
Induction of resistance
Cp cells were incubated with RumC1 or metronidazole as described 
above for MIC determination. After 24 hours of incubation, the well 
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with the highest concentration of peptide or antibiotic showing visible 
growth was used to inoculate a new culture that was then treated 
again. These steps were repeated daily for 30 days to follow MIC 
changes.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/9/eaaw9969/DC1
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